Smartleaf Asset Management’s Neurogene NGNE Stock Holding History

Smartleaf Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10	Closed	-$403	–	2983
2024 Q3	$403	Buy	+10	New	+$388	﹤0.01%	2809

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Smartleaf Asset Management's NGNE Position: Q4 2024 in Review

Smartleaf Asset Management sold out of Neurogene (NGNE) in Q4 2024, closing a stake of 10 shares — an estimated $403 sold.

Smartleaf Asset Management first reported a position in NGNE in Q3 2024 and held it in 1 quarter. The position peaked at $403 in Q3 2024. 88 funds tracked by Wall St. Rank hold NGNE as of Q4 2024.

Smartleaf Asset Management reported no remaining Neurogene position as of Q4 2024 after selling out during the quarter.
Smartleaf Asset Management sold 10 Neurogene shares in Q4 2024, an estimated $403.
Smartleaf Asset Management first reported a position in Neurogene in Q3 2024 and held it in 1 quarter.
Smartleaf Asset Management's Neurogene position peaked at $403 in Q3 2024.
88 funds tracked by Wall St. Rank held Neurogene as of Q4 2024.

Based on Smartleaf Asset Management's 13F filing for Q4 2024, filed 5 Feb 2025.